We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Hemispherx Biopharma nets $14.2mm with private sale of shares
16 Jun 2009
Executive Summary
Hemispherx Biopharma (developing infectious disease, cancer, and immunology drug candidates) has netted $14.2mm through the sale of 13.6mm shares at $1.10 each (a 53% premium) to two institutional investors. The backers also received Series A warrants to buy another 6.1mm common shares; the Series I five-year warrants enable the holder to purchase shares for $1.65 each and the Series II warrants are exercisable for 3mm shares within 45 days at $1.10. Rodman & Renshaw was the placement agent.
Deal Industry
Pharmaceuticals
Pharmaceuticals
Vaccines
Drug Delivery
Macromolecule
Biotechnology
Large Molecule
Deal Status
Final
Deal Type
Financing
Private Investment in Public Equity
Private Placement
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?